HERTHENA-Lung02
ASO Keyword Dashboard
Tracking 25 keywords for HERTHENA-Lung02 in Google Play
HERTHENA-Lung02 tracks 25 keywords (no keywords rank yet; 25 need traction). Key metrics: opportunity 71.3, difficulty 43.1.
Solely intended for participants in the Daiichi Sankyo HERTHENA Lung02 study
Tracked keywords
25
0 ranked • 25 not ranking yet
Top 10 coverage
—
Best rank — • Latest leader —
Avg opportunity
71.3
Top keyword: participants
Avg difficulty
43.1
Lower scores indicate easier wins
Opportunity leaders
- 60.7
participants
Opportunity: 74.0 • Difficulty: 36.9 • Rank —
Competitors: 87
- 61.0
solely
Opportunity: 74.0 • Difficulty: 37.7 • Rank —
Competitors: 272
- 62.4
locally
Opportunity: 74.0 • Difficulty: 41.7 • Rank —
Competitors: 259
- 68.6
functionality
Opportunity: 73.0 • Difficulty: 63.0 • Rank —
Competitors: 964
- 58.2
phase
Opportunity: 73.0 • Difficulty: 36.3 • Rank —
Competitors: 169
Unranked opportunities
participants
Opportunity: 74.0 • Difficulty: 36.9 • Competitors: 87
solely
Opportunity: 74.0 • Difficulty: 37.7 • Competitors: 272
locally
Opportunity: 74.0 • Difficulty: 41.7 • Competitors: 259
functionality
Opportunity: 73.0 • Difficulty: 63.0 • Competitors: 964
phase
Opportunity: 73.0 • Difficulty: 36.3 • Competitors: 169
High competition keywords
allows
Total apps: 177,209 • Major competitors: 6,475
Latest rank: — • Difficulty: 52.9
complete
Total apps: 170,581 • Major competitors: 9,574
Latest rank: — • Difficulty: 53.1
based
Total apps: 151,450 • Major competitors: 5,846
Latest rank: — • Difficulty: 55.0
advanced
Total apps: 88,279 • Major competitors: 5,320
Latest rank: — • Difficulty: 52.7
contains
Total apps: 66,707 • Major competitors: 2,156
Latest rank: — • Difficulty: 47.5
All tracked keywords
Includes opportunity, difficulty, rankings and competitor benchmarks
| Major Competitors | |||||||
|---|---|---|---|---|---|---|---|
| medical | 71 | 100 | 44 | 72 34,083 competing apps Median installs: 1,242 Avg rating: 3.9 | — | — | 912 major competitor apps |
| created | 70 | 100 | 48 | 76 55,629 competing apps Median installs: 1,988 Avg rating: 4.1 | — | — | 2,180 major competitor apps |
| small | 70 | 100 | 49 | 76 57,941 competing apps Median installs: 2,160 Avg rating: 4.1 | — | — | 2,940 major competitor apps |
| complete | 67 | 100 | 53 | 83 170,581 competing apps Median installs: 2,483 Avg rating: 4.1 | — | — | 9,574 major competitor apps |
| contains | 69 | 100 | 48 | 77 66,707 competing apps Median installs: 5,001 Avg rating: 4.2 | — | — | 2,156 major competitor apps |
| allows | 67 | 100 | 53 | 84 177,209 competing apps Median installs: 1,465 Avg rating: 3.9 | — | — | 6,475 major competitor apps |
| advanced | 69 | 100 | 53 | 79 88,279 competing apps Median installs: 2,144 Avg rating: 4.0 | — | — | 5,320 major competitor apps |
| functionality | 73 | 100 | 63 | 69 20,360 competing apps Median installs: 1,924 Avg rating: 3.9 | — | — | 964 major competitor apps |
| participants | 74 | 100 | 37 | 61 6,510 competing apps Median installs: 584 Avg rating: 4.0 | — | — | 87 major competitor apps |
| based | 67 | 100 | 55 | 82 151,450 competing apps Median installs: 1,465 Avg rating: 4.0 | — | — | 5,846 major competitor apps |
| phase | 73 | 100 | 36 | 58 4,512 competing apps Median installs: 953 Avg rating: 4.1 | — | — | 169 major competitor apps |
| growth | 73 | 100 | 42 | 68 19,927 competing apps Median installs: 817 Avg rating: 4.1 | — | — | 621 major competitor apps |
| exclusively | 73 | 100 | 41 | 67 17,049 competing apps Median installs: 736 Avg rating: 3.9 | — | — | 438 major competitor apps |
| solely | 74 | 100 | 38 | 61 6,785 competing apps Median installs: 2,096 Avg rating: 4.0 | — | — | 272 major competitor apps |
| study | 70 | 100 | 48 | 75 53,982 competing apps Median installs: 1,326 Avg rating: 4.3 | — | — | 1,201 major competitor apps |
| cell | 73 | 100 | 43 | 67 16,759 competing apps Median installs: 1,981 Avg rating: 4.1 | — | — | 862 major competitor apps |
| factor | 73 | 100 | 37 | 58 4,596 competing apps Median installs: 2,824 Avg rating: 3.8 | — | — | 217 major competitor apps |
| cancer | 71 | 100 | 31 | 50 1,388 competing apps Median installs: 1,006 Avg rating: 4.2 | — | — | 39 major competitor apps |
| failure | 72 | 100 | 34 | 53 2,067 competing apps Median installs: 3,814 Avg rating: 4.0 | — | — | 115 major competitor apps |
| intended | 72 | 100 | 48 | 69 21,081 competing apps Median installs: 1,656 Avg rating: 4.0 | — | — | 696 major competitor apps |
| therapy | 73 | 100 | 36 | 59 5,124 competing apps Median installs: 918 Avg rating: 4.0 | — | — | 103 major competitor apps |
| locally | 74 | 100 | 42 | 62 8,258 competing apps Median installs: 636 Avg rating: 4.0 | — | — | 259 major competitor apps |
| label | 73 | 100 | 36 | 56 3,401 competing apps Median installs: 2,061 Avg rating: 3.9 | — | — | 177 major competitor apps |
| versus | 71 | 100 | 38 | 48 1,085 competing apps Median installs: 7,846 Avg rating: 4.0 | — | — | 107 major competitor apps |
| lung | 70 | 100 | 26 | 43 484 competing apps Median installs: 1,225 Avg rating: 4.0 | — | — | 10 major competitor apps |
App Description
Solely intended for participants in the Daiichi Sankyo HERTHENA Lung02 study
The Daiichi Sankyo HERTHENA–Lung02 study is a Phase 3, randomized, open-label study of Patritumab Deruxtecan versus platinum-based chemotherapy in metastatic or locally advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) after failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) therapy